Metabolic's neuropathic pain drug ACV reveal greater potential in preclinical studies
28-Nov-2006
The development programme for an oral version of ACV1 will run alongside the current Phase 2A clinical programme for the injected version of ACV1.
Most read news
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.